MarginsXMarginsX
Home › Markets › Health Care › AVBP

ArriVent BioPharma Inc. (AVBP)

AVBP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.56
-11.15% on the day
Market cap
$597.9M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerAVBP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001868279
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
8.9 months
$113.6M cash at September 30, 2026
Share count, 1 year
+25.3%
2025-11-07 to 2026-11-05
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$13.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$113.6M cash; operating cash flow -$38.2M a quarter.Report 2026-09-30
Shares outstanding51,723,074 (2026-11-05); 41,281,361 a year earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-05-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months8-K 4.01 2025-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $13.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$5.0M-$40.3M-$40.7M$113.6MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$49.9M-$39.6M$154.7MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$43.3M-$41.9M$62.1MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$35.5M-$30.7M$45.5MNo debt tagsNeeds four quarters10-K 2026-03-05
Q3 2025
2025-09-30
Not filed-$35.0M-$35.8M$112.7MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$31.4M-$26.1M$112.8MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$64.4M-$68.0M$49.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
Not filed-$20.6M-$16.2M$74.3MNo debt tagsNeeds four quarters10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-11
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-09
Latest current report
FORM 8-K
8-K2026-11-09
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 162 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.6%
1 month-19.1%
3 months-56.6%
Year to date-35.3%
1 year-33.9%
From 52-week high-62.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GERNGeron Corporation$0.9419-2.60%$606.8M
CLYMClimb Bio Inc.$9.94-4.05%$583.9M
ABUSArbutus Biopharma Corporation$4.04-1.22%$619.3M
ACRSAclaris Therapeutics Inc.$3.60-8.04%$571.8M
IMMXImmix Biopharma Inc.$7.48-4.59%$626.9M
WVEWave Life Sciences Inc.$2.87-8.31%$566.0M
DSGNDesign Therapeutics Inc.$9.92-5.25%$635.2M
HELPHelus Pharma Inc.$7.67-13.53%$560.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier